CLINICAL TRIALS PROFILE FOR GALLIUM GA-68 EDOTREOTIDE
✉ Email this page to a colleague
All Clinical Trials for GALLIUM GA-68 EDOTREOTIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT03001349 ↗ | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | Terminated | National Cancer Institute (NCI) | Early Phase 1 | 2017-05-16 | This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors. |
NCT03001349 ↗ | 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors | Terminated | M.D. Anderson Cancer Center | Early Phase 1 | 2017-05-16 | This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for GALLIUM GA-68 EDOTREOTIDE
Condition Name
Condition Name for GALLIUM GA-68 EDOTREOTIDE | |
Intervention | Trials |
Multiple Endocrine Neoplasia Type 1 | 1 |
Neuroendocrine Neoplasm | 1 |
Somatostatin Positive Neoplastic Cells Present | 1 |
Von Hippel-Lindau Syndrome | 1 |
[disabled in preview] | 0 |
This preview shows a limited data set Subscribe for full access, or try a Trial |
Clinical Trial Locations for GALLIUM GA-68 EDOTREOTIDE
Trials by Country
Clinical Trial Progress for GALLIUM GA-68 EDOTREOTIDE
Clinical Trial Phase
Clinical Trial Sponsors for GALLIUM GA-68 EDOTREOTIDE
Sponsor Name